目的：探讨复方血栓通胶囊联合羟苯磺酸钙治疗早期糖尿病性视网膜病变(DR)患者的临床疗效。

方法：选择2015-02/2016-11我院眼科门诊收治的DR患者54例68眼，按照随机数字表法，将患者分为对照组(27例34眼)和研究组(27例34眼)。对照组患者给予口服羟苯磺酸钙片进行治疗，而研究组患者在对照组基础上联合使用复方血栓通胶囊进行治疗。两组患者的疗程均为5mo。统计两组患者临床总有效率，同时分别于治疗前后检测两组患者视力、血糖及炎症因子水平，并观察不良反应及复发率。

结果：研究组患者的临床总有效率为91%(31/34)，明显高于对照组68%(23/34)，差异有统计学意义(P<0.05)； 与治疗前相比，两组患者治疗后视力、血管瘤体积、黄斑厚度、出血斑面积、视野灰度值、血糖及炎症因子水平显著下降，同时研究组患者的视力、血糖及炎症指标水平改善情况明显优于对照组，且差异均具有统计学意义(P<0.05)； 两组患者治疗期间均未发生不良反应； 研究组患者复发率为3%(1/31)，明显低于对照组的26%(6/23)，差异有统计学意义(P=0.039)。

结论：复方血栓通胶囊联合羟苯磺酸钙治疗DR疗效显著，能够明显改善视力、血糖及减轻炎症反应，具有较好的远期疗效。

METHODS: According to the random table method, 54 cases of DR patients(68 eyes)in the ophthalmological clinic of our hospital from February 2015 to November 2016 were divided into control group and research group with 27 cases(34 eyes)in each group. Patients in the control group were treated with calcium dobesilate tablets, while patients in the research group were treated with compound xueshuantong capsule based on the control group. The duration of treatment was 5mo in both groups. The total clinical efficiency of the two groups was calculated, and the visual, blood glucose and inflammatory factors of the two groups were detected before and after treatment, in addition the adverse reaction and recurrence rate were observed.

RESULTS: The total clinical efficiency of the patients in the research group was 91%(31/34), which was significantly higher than 68%(23/34)of the control group(P<0.05). Compared with before treatment, the vision, the volume of hemangioma, macular thickness, plaque area, grey value view, blood glucose and inflammatory factor levels of two groups of patients after treatment dropped significantly, meanwhile the vision, blood sugar and inflammation index levels of research group were better than control group, and the differences were statistically significant(P<0.05). No adverse reactions occurred during the treatment of the two groups. The recurrence rate of research group was 3%(1/31), which was significantly lower than that of the control group as 26%(6/23)(P=0.039).

CONCLUSION: The curative effect of compound xueshuantong capsule combined with calcium dobesilate in the treatment of patients with early DR is significant. It can significantly improve eyesight, blood glucose and inflammatory response and has a good forward curative effect.